Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CHMP2B protein targeted inhibitor and application thereof in ischemic heart disease

A CHMP2B, ischemic heart disease technology, applied in cardiovascular system diseases, organic active ingredients, medical preparations containing active ingredients, etc. Effects of cell death, improved prognosis, and alleviation of myocardial dysfunction

Pending Publication Date: 2021-05-28
AIR FORCE MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, drugs for ischemic heart disease mainly rely on drugs such as statins, nitrates, and β-receptor antagonists, but these drugs cannot fundamentally cure ischemic heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CHMP2B protein targeted inhibitor and application thereof in ischemic heart disease
  • CHMP2B protein targeted inhibitor and application thereof in ischemic heart disease
  • CHMP2B protein targeted inhibitor and application thereof in ischemic heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Experimental research on the relationship between myocardial CHMP2B protein level, myocardial autophagy function, and myocardial ischemia injury

[0048] 1. Materials and Experimental Design

[0049] 1.1 In vivo experiments

[0050] 1.1.1 Experimental materials

[0051] Male C57BL / 6J mice (3-4 months old) were purchased from the Experimental Animal Center of Fourth Military Medical University. This study was approved by the Experimental Animal Ethics Committee of the Fourth Military Medical University (IACUC-20200602). Animals were housed on a 12:12 h day / night pattern with free access to food and drink.

[0052] 1.1.2 Experimental grouping and administration

[0053] The mice were randomly divided into treatment group and control group. The treatment group was given metformin hydrochloride (100 mg / kg / d) by Beijing Solarbiol Co., Ltd. by intraperitoneal injection, and normal saline was used as control, and the administration was continued for 7 days. Th...

Embodiment 2 2

[0099] The preparation of embodiment 2 metformin tablet

[0100] The metformin hydrochloride is mixed with conventional auxiliary materials, and the metformin hydrochloride tablet is prepared according to a conventional method. Oral, 0.25g for an adult, 3 times a day.

Embodiment 3 2

[0101] The preparation of embodiment 3 metformin sustained-release tablets

[0102] The metformin hydrochloride is mixed with conventional auxiliary materials, and the metformin hydrochloride sustained-release tablet is prepared according to a conventional method. Oral, 0.5g for an adult, once a day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to a CHMP2B protein targeted inhibitor and application thereof in preparation of medicines for preventing or treating ischemic heart disease. The invention provides an important theoretical basis for the CHMP2B protein targeted inhibitor to treat ischemic heart disease, and provides a new drug solution for the prevention and treatment of ischemic heart disease in the prior art. Meanwhile, a new pharmaceutical application is explored for the known medicine metformin or the medicinal salt thereof, and the treatment range of the medicine is widened.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a CHMP2B protein targeting inhibitor and its application in ischemic heart disease. Background technique [0002] According to the "China Cardiovascular Disease Report 2019", cardiovascular disease is the leading cause of death among Chinese people, higher than tumors and other diseases. Among them, myocardial infarction caused by coronary heart disease is an important cause of mortality and disability among Chinese people. At present, the overall incidence of coronary heart disease is still on the rise and remains high. Most patients have poor quality of life after percutaneous coronary intervention, and there is currently no cure. [0003] Cardiomyocytes are highly differentiated terminal cells. Abnormal events or protein instability in the process of cell survival are mainly completed by the cells themselves, which efficiently, reliably and accurately degrade an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/155A61P9/10
CPCA61K31/155A61P9/10
Inventor 马恒李天穆楠余璐
Owner AIR FORCE MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com